person · Reporting owner

Curran Terrie

Disclosed activity across 4 companies

Tapewire entity: 18725
SEC CIK: 0001690298

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Arcutis Biotherapeutics, Inc.ARQT · Entity 4236	Director	August 27, 2026	August 28, 2026
Phathom Pharmaceuticals, Inc.PHAT · Entity 5177	Director · President and Chief Executive	February 27, 2025	March 03, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Arcutis Biotherapeutics, Inc.

Report date August 27, 2026 · Filed August 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	23,526	Ending reported balance After 2026-08-27 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-08-27 · Exercise / conversion · Acquired 11,148 · Balance 34,674 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Row 2 · 2026-08-27 · Sale · Disposed 11,148 · Balance 23,526 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2026-08-27 · Exercise / conversion · Acquired 27,052 · Balance 50,578 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Row 4 · 2026-08-27 · Sale · Disposed 27,052 · Balance 23,526 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.51 · Expires 2033-05-31	Direct	0	Reported balance After 2026-08-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-08-27 · Exercise / conversion · Disposed 11,148 · Balance 0 F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F4: The option is fully vested.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.63 · Expires 2034-06-14	Direct	0	Reported balance After 2026-08-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-08-27 · Exercise / conversion · Disposed 27,052 · Balance 0 F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F4: The option is fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service.

F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.1001 inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service.

F4: The option is fully vested.

Phathom Pharmaceuticals, Inc.

Report date February 27, 2025 · Filed March 03, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.76 · Expires 2035-02-26	Direct	342,500	Reported balance After 2025-02-27 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-02-27 · Grant · Acquired 342,500 · Balance 342,500 F1: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest with respect to 25% of the shares of common stock on February 27, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CELGENE CORP /DE/

Report date November 20, 2019 · Filed November 22, 2019

Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2019-11-20 · Disposition to issuer · Disposed 3,426 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-20 · Disposition to issuer · Disposed 1,857 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-11-20 · Disposition to issuer · Disposed 6,593 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-11-20 · Disposition to issuer · Disposed 4,120 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2019-11-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-11-20 · Disposition to issuer · Disposed 27,749 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.

F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement.

Myovant Sciences Ltd.

Report date March 10, 2023 · Filed March 10, 2023

Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	Reported balance After 2023-03-10 transaction · row 1 1 source row Row 1 · 2023-03-10 · Disposition to issuer · Disposed 3,673 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time. F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.30 · Expires 2026-11-14	Direct	Reported balance After 2023-03-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-03-10 · Disposition to issuer · Disposed 33,846 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.68 · Expires 2027-05-14	Direct	Reported balance After 2023-03-10 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-03-10 · Disposition to issuer · Disposed 11,154 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.14 · Expires 2027-08-17	Direct	Reported balance After 2023-03-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-03-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.25 · Expires 2028-08-30	Direct	Reported balance After 2023-03-10 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-03-10 · Disposition to issuer · Disposed 22,500 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22	Direct	Reported balance After 2023-03-10 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-03-10 · Disposition to issuer · Disposed 5,250 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.47 · Expires 2030-09-14	Direct	Reported balance After 2023-03-10 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-03-10 · Disposition to issuer · Disposed 21,603 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.71 · Expires 2031-11-04	Direct	Reported balance After 2023-03-10 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-03-10 · Disposition to issuer · Disposed 21,096 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: These options are fully vested.

Filing footnotes · ownership attribution and instrument terms

F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").

F2: Reflects the vested portion of 9,859 restricted stock units ("RSUs") granted to the Reporting Person as the annual non-employee director grant, which pro-ration was calculated based on the number of days the Reporting Person had served as a director from October 26, 2022 to the effective time of the Merger (the "Effective Time") (by using 365 days for a full year), which was equal to 3,673 (rounded down to the nearest whole RSU). Such vested RSUs were converted into the RSU Consideration (as defined below). The remaining 6,186 unvested RSUs were forfeited without consideration as of the Effective Time.

F3: Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"), multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time (the "RSU Consideration").

F4: These options are fully vested.

F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 09, 2021 Filed Sep 13, 2021 20:11 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Exercise / conversionStock Option (Right to Buy) · Derivative	4,850	$0.00 Strike: $7.65	$0.00	Disclosure SEC source: 0001209191-21-055667 · doc4.xml · derivative · entry 3 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,250 Underlying: Common Shares · 4,850 shares Expires 2029-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document
September 09, 2021 Filed Sep 13, 2021 20:11 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	4,850	$25.58	$124,063.00	Disclosure SEC source: 0001209191-21-055667 · doc4.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $25.42 to $25.72. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 09, 2021 Filed Sep 13, 2021 20:11 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Exercise / conversionCommon Shares	4,850	$7.65	$37,102.50	Disclosure SEC source: 0001209191-21-055667 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 02, 2021 Filed Sep 3, 2021 20:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Exercise / conversionStock Option (Right to Buy) · Derivative	37,135	$0.00 Strike: $7.65	$0.00	Disclosure SEC source: 0001209191-21-054758 · doc4.xml · derivative · entry 6 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,100 Underlying: Common Shares · 37,135 shares Expires 2029-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
September 02, 2021 Filed Sep 3, 2021 20:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	37,135	$25.03	$929,489.05	Disclosure SEC source: 0001209191-21-054758 · doc4.xml · nonDerivative · entry 4 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F3 · price: The shares were sold at prices ranging from $25.00 to $25.10. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 02, 2021 Filed Sep 3, 2021 20:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Exercise / conversionCommon Shares	37,135	$7.65	$284,082.75	Disclosure SEC source: 0001209191-21-054758 · doc4.xml · nonDerivative · entry 3 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,135 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 01, 2021 Filed Sep 3, 2021 20:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Exercise / conversionStock Option (Right to Buy) · Derivative	11,373	$0.00 Strike: $7.65	$0.00	Disclosure SEC source: 0001209191-21-054758 · doc4.xml · derivative · entry 5 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,235 Underlying: Common Shares · 11,373 shares Expires 2029-08-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document
September 01, 2021 Filed Sep 3, 2021 20:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	SaleCommon Shares	11,373	$25.00	$284,325.00	Disclosure SEC source: 0001209191-21-054758 · doc4.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Shares sold pursuant to a 10b5-1 trading plan. F2 · price: The shares were sold at prices ranging from $25.00 to $25.01. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
September 01, 2021 Filed Sep 3, 2021 20:25 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	Exercise / conversionCommon Shares	11,373	$7.65	$87,003.45	Disclosure SEC source: 0001209191-21-054758 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,373 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 09, 2021 Filed Jun 11, 2021 20:36 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (Right to Buy) · Derivative	13,391	$0.00 Strike: $27.77	$0.00	Disclosure SEC source: 0001567619-21-012026 · doc1.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,391 Underlying: Common Stock · 13,391 shares Expires 2031-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of (i) the first anniversary of June 9, 2021 or (ii) the next Annual Meeting following June 9, 2021, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document
March 22, 2021 Filed Mar 23, 2021 23:22 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	Exercise / conversionStock Option (Right to Buy) · Derivative	11,513	$0.00 Strike: $6.95	$0.00	Disclosure SEC source: 0001209191-21-022705 · doc4.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 855,687 Underlying: Common Stock · 11,513 shares Expires 2029-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option was granted on August 29, 2019 and vested with respect to 25% of the shares of common stock on August 29, 2020, and thereafter vests in equal monthly installments over the following three years. Read SEC document
March 22, 2021 Filed Mar 23, 2021 23:22 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	1,140	$44.08	$50,255.53	Disclosure SEC source: 0001209191-21-022705 · doc4.xml · nonDerivative · entry 3 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.82 to $44.71. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 22, 2021 Filed Mar 23, 2021 23:22 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	SaleCommon Stock	10,373	$43.24	$448,495.33	Disclosure SEC source: 0001209191-21-022705 · doc4.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,140 F2 · kind: All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.82 to $43.81. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
March 22, 2021 Filed Mar 23, 2021 23:22 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	Exercise / conversionCommon Stock	11,513	$6.95	$80,015.35	Disclosure SEC source: 0001209191-21-022705 · doc4.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,513 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercising a stock option. Read SEC document
January 28, 2021 Filed Jan 29, 2021 21:27 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	225,000	$0.00 Strike: $39.11	$0.00	Disclosure SEC source: 0001209191-21-006094 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document
November 02, 2020 Filed Nov 4, 2020 21:34 UTC	Arcutis Biotherapeutics, Inc. ARQT · Entity 4236	GrantStock Option (Right to Buy) · Derivative	37,500	$0.00 Strike: $18.72	$0.00	Disclosure SEC source: 0001567619-20-018694 · doc1.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option vests as to 1/3 of the total shares on each of November 2, 2021, November 2, 2022 and November 2, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document
September 15, 2020 Filed Sep 17, 2020 20:16 UTC	Myovant Sciences Ltd. MYOV · Entity 115677	GrantStock Option (Right to Buy) · Derivative	21,603	$0.00 Strike: $21.47	$0.00	Disclosure SEC source: 0001209191-20-050882 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,603 Underlying: Common Shares · 21,603 shares Expires 2030-09-14 F1 · derivative.exercise_date: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) September 15, 2021, and (b) the date that is one day prior to the Issuer's 2021 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. Read SEC document
July 01, 2020 Filed Jul 2, 2020 20:44 UTC	Phathom Pharmaceuticals, Inc. PHAT · Entity 5177	GrantStock Option (Right to Buy) · Derivative	175,000	$0.00 Strike: $32.20	$0.00	Disclosure SEC source: 0001209191-20-040392 · doc4.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · Director · President and Chief Executive 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2030-06-30 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the shares of common stock on July 1, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Company on the applicable vesting dates. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	12,983	$0.00 Strike: $71.43	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 26 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,983 shares Expires 2028-10-29 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	12,983	$0.00 Strike: $88.91	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 25 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,983 shares Expires 2028-07-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	12,982	$0.00 Strike: $83.13	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 24 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,982 shares Expires 2028-05-08 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	6,777	$0.00 Strike: $103.26	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 23 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,777 shares Expires 2028-01-29 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	15,659	$0.00 Strike: $100.97	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 22 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,659 shares Expires 2027-10-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	6,776	$0.00 Strike: $135.41	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 21 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,776 shares Expires 2027-07-31 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	6,776	$0.00 Strike: $124.06	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 20 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,776 shares Expires 2027-05-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	6,563	$0.00 Strike: $113.18	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 19 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,563 shares Expires 2027-01-30 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	6,562	$0.00 Strike: $102.18	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 18 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,562 shares Expires 2026-10-31 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	3,125	$0.00 Strike: $114.69	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 17 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2026-08-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	3,125	$0.00 Strike: $104.97	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 16 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,125 shares Expires 2026-05-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $100.80	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 15 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-02-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $114.08	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 14 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2025-11-09 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $132.56	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 13 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2025-07-27 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	2,500	$0.00 Strike: $109.90	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 12 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2025-05-04 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $118.57	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 11 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-02-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	7,050	$0.00 Strike: $117.18	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 10 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,050 shares Expires 2024-12-19 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $103.10	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 9 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2024-10-27 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $87.64	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 8 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,500 shares Expires 2024-07-28 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	3,750	$0.00 Strike: $81.56	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 7 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,750 shares Expires 2023-12-02 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerStock Option (right to buy) · Derivative	5,500	$0.00 Strike: $58.33	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · derivative · entry 6 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires 2023-05-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option is fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	327	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · nonDerivative · entry 5 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Indirect · 401(k) Plan Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerCommon Stock	37,181	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · nonDerivative · entry 4 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Reflects disposition in connection with the Merger Agreement. Upon the Effective Time, each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one CVR issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantCommon Stock	17,840	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · nonDerivative · entry 3 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,181 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantCommon Stock	9,889	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · nonDerivative · entry 2 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,341 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	GrantCommon Stock	5,139	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001375 · form4-11222019_071104.xml · nonDerivative · entry 1 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,452 F1 · price: Represents shares of Celgene common stock acquired in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS. These shares were deemed acquired upon satisfaction of performance criteria applicable to Celgene performance-based restricted stock units at the effective time of such merger (the "Effective Time"). In accordance with the Merger Agreement, these performance-based restricted stock units were assumed by BMS and converted into service-based restricted stock units relating to BMS common stock and contingent value rights ("CVRs") in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	27,749	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001376 · form4-11222019_071108.xml · derivative · entry 5 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,749 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.expiration_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	4,120	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001376 · form4-11222019_071108.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,120 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.expiration_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	6,593	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001376 · form4-11222019_071108.xml · derivative · entry 3 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,593 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.expiration_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	1,857	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001376 · form4-11222019_071108.xml · derivative · entry 2 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,857 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.expiration_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
November 20, 2019 Filed Nov 22, 2019 07:31 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Disposition to issuerRestricted Stock Unit · Derivative	3,426	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001415889-19-001376 · form4-11222019_071108.xml · derivative · entry 1 Curran Terrie · CIK 0001690298 · PRES., GLBL INFLAM. AND IMMUN. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,426 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F2 · price: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.expiration_date: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and contingent value rights in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document
October 31, 2019 Filed Nov 4, 2019 16:05 UTC	CELGENE CORP /DE/ CELG · Entity 15781	Exercise / conversionRestricted Stock Unit · Derivative	3,281	$0.00	$0.00	Disclosure SEC source: 0001415889-19-001256 · form4-11042019_041110.xml · derivative · entry 4 Curran Terrie · CIK 0001690298 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,281 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The restricted stock units granted to the reporting person on October 31, 2016 have vested and settled for shares of the Company's common stock. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.